Molbio Diagnostics
1,434.50
-7.80(-0.54%)
Market Cap₹16,531.18 Cr
PE Ratio101.34
Industry-
Company Performance:
1D-0.54%
1M-0.26%
6M+77.76%
1Y+77.76%
5Y+77.76%
View Company Insightsright
More news about Molbio Diagnostics
23Sept 26
Molbio Diagnostics shares worth ₹365.64 crore flag large-trade signal
Approximately 27,80,549 Molbio Diagnostics shares changed hands on BSE, flagged as a large-trade signal. The shares traded at ₹1,315.00 per share, for a combined value of ₹365.64 crore. This is a real-time signal from a trade-scanning system, not a confirmed exchange-level event. Buyer, seller, and client identities are not known; official disclosures are made by the exchange only after market close.
 no imag found
17Sept 26
Molbio Diagnostics hosts investor meet on Sep 22 at 11:00 am
Molbio Diagnostics hosts virtual investor meet on September 22, 2026. Session begins at 11:00 am IST for a group of investors and analysts. Discussion limited to general business outlook and public information. No unpublished price-sensitive information will be disclosed.
 no imag found
12Sept 26
Molbio Diagnostics Q1FY27 net profit up 523% to ₹52.7 crore on deferred exports
Consolidated net profit surged 523% YoY to ₹52.7 crore in Q1FY27, driven by ₹57 crore in deferred export revenue recognition. Revenue rose fourfold to ₹411.5 crore, with management guiding for ~25% top-line growth and 24-25% EBITDA margin for FY27. Company sold 164 devices and 62.4 lakh kits; capacity utilization stands at 42% for devices and 58% for test kits. OptraScan received US FDA clearance for digital pathology solutions, with meaningful revenue contribution expected from FY28. Prognosys contributed ₹11 crore to Q1 revenue, with full-year EBITDA margins expected near 19%.
 no imag found
02Sept 26
Molbio Diagnostics hosts Q1FY27 earnings call on Sep 8
Molbio Diagnostics schedules earnings call for Sep 8, 2026, at 4:00 pm IST. Discussion focuses on Q1FY27 results for the quarter ended June 30, 2026. CEO Sriram Natarajan and CFO Manan Bimal Khokhani among key participants. Disclosure made under SEBI LODR Regulation 30.
 no imag found
Molbio Diagnostics
1,434.50
-7.80
(-0.54%)
1 Year Returns:+77.76%